Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAREON-Lung-1 in first-line extensive-stage small cell lung cancer
2025-520565-51-00Phase 3Authorised
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2026
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 42
01
Overview
Phase 3, randomised, open-label trial in small cell lung cancer (SCLC) comparing Obrixtamig combination arm with Standard of care control arm (2 arms). Primary endpoint: Overall survival. Planned start Jun 2026; status: authorised.
02
Drugs
obrixtamig
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on 2025-520565-51-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-520565-51-00.